GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Terns Pharmaceuticals Inc (NAS:TERN) » Definitions » Forward PE Ratio

Terns Pharmaceuticals (Terns Pharmaceuticals) Forward PE Ratio : 0.00 (As of Jun. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Terns Pharmaceuticals Forward PE Ratio?

Terns Pharmaceuticals's Forward PE Ratio for today is 0.00.

Terns Pharmaceuticals's PE Ratio without NRI for today is 0.00.

Terns Pharmaceuticals's PE Ratio for today is 0.00.


Terns Pharmaceuticals Forward PE Ratio Historical Data

The historical data trend for Terns Pharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Terns Pharmaceuticals Forward PE Ratio Chart

Terns Pharmaceuticals Annual Data
Trend
Forward PE Ratio

Terns Pharmaceuticals Quarterly Data
Forward PE Ratio

Competitive Comparison of Terns Pharmaceuticals's Forward PE Ratio

For the Biotechnology subindustry, Terns Pharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Terns Pharmaceuticals's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Terns Pharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Terns Pharmaceuticals's Forward PE Ratio falls into.



Terns Pharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Terns Pharmaceuticals  (NAS:TERN) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Terns Pharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Terns Pharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Terns Pharmaceuticals (Terns Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1065 East Hillsdale Boulevard, Suite 100, Foster, CA, USA, 94404
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases.
Executives
Mark J. Vignola officer: Chief Financial Officer C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Seokho Bryan Yoon officer: COO and General Counsel NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Senthil Vel Sundaram director, officer: Chief Executive Officer NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Hongbo Lu director C/O AVEDRO, INC., 201 JONES ROAD, WALTHAM MA 02451
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Lav Biosciences Fund V, L.p. 10 percent owner C/O ESTERA TRUST (CAYMAN) LIMITED, 75 FORT STREET, PO BOX 1350, GRAND CAYMAN E9 KY1-1108
Lav Aqua Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Hopewell Resources Holdings Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Oriental Spring Venture Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Orbimed Capital Gp Vii Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Iii Ltd director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Orbimed Asia Gp Iii, L.p. director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629